In 1979, Dr. William Campbell, a research scientist working for Merck and Company, discovered evidence that one of the company’s drugs might kill the parasite that causes river blindness. He then decided to request permission to research this new finding. The mangers for the company noticed that it would take enormous amount of funding and time to develop this new vaccine.
This new product could be really hard to market and who was going to actually buy it; it could also damaged the market share that Merck currently had by selling the animal version of the vaccine Ivermectin. Despite all of this, Dr. P. Roy Vagelos chairman of Merck and Company and his fellow managers approved the necessary funding for the research